Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ATRX OTCMKTS:GLGLF OTCMKTS:NXEN NASDAQ:VIRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRXAdhera Therapeutics$0.01$0.00$0.00▼$0.01$116K4167 shs2 shsGLGLFGLG Life Tech$0.01$0.01▼$1.12$430K1.91N/AN/ANXENNexien Biopharma$0.00-75.4%$0.01$0.00▼$0.05$99K-1.08686 shs278 shsVIRXViracta Therapeutics$0.01$0.01$0.01▼$0.56$389K1.061.11 million shsN/ABeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRXAdhera Therapeutics0.00%0.00%+9,900.00%+9,900.00%+25.00%GLGLFGLG Life Tech0.00%0.00%0.00%0.00%0.00%NXENNexien Biopharma0.00%-75.44%-75.44%-85.57%-91.95%VIRXViracta Therapeutics0.00%0.00%0.00%-43.47%-96.61%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATRXAdhera TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AGLGLFGLG Life TechN/AN/AN/AN/AN/AN/AN/AN/ANXENNexien BiopharmaN/AN/AN/AN/AN/AN/AN/AN/AVIRXViracta Therapeutics1.7832 of 5 stars3.33.00.00.00.60.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATRXAdhera Therapeutics 0.00N/AN/AN/AGLGLFGLG Life Tech 0.00N/AN/AN/ANXENNexien Biopharma 0.00N/AN/AN/AVIRXViracta Therapeutics 2.50Moderate Buy$1.1311,403.07% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATRXAdhera TherapeuticsN/AN/AN/AN/AN/AN/AGLGLFGLG Life Tech$10.62M0.00N/AN/A($2.00) per share0.00NXENNexien BiopharmaN/AN/AN/AN/A($0.01) per shareN/AVIRXViracta TherapeuticsN/AN/AN/AN/A$0.33 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATRXAdhera Therapeutics-$2.11MN/A0.00∞N/AN/AN/AN/AN/AGLGLFGLG Life Tech$48.29M$1.320.00N/AN/A498.04%N/A-76.15%N/ANXENNexien Biopharma-$240KN/A0.00∞N/AN/AN/A-4,015.59%N/AVIRXViracta Therapeutics-$51.06M-$1.10N/A∞N/AN/A-1,899.61%-114.21%N/ALatest ATRX, GLGLF, NXEN, and VIRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/30/2025Q1 2025GLGLFGLG Life TechN/A-$0.06N/A-$0.05N/A$2.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATRXAdhera TherapeuticsN/AN/AN/AN/AN/AGLGLFGLG Life TechN/AN/AN/AN/AN/ANXENNexien BiopharmaN/AN/AN/AN/AN/AVIRXViracta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATRXAdhera TherapeuticsN/AN/AN/AGLGLFGLG Life TechN/A0.210.19NXENNexien BiopharmaN/A0.020.02VIRXViracta TherapeuticsN/A0.760.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATRXAdhera TherapeuticsN/AGLGLFGLG Life TechN/ANXENNexien BiopharmaN/AVIRXViracta Therapeutics31.37%Insider OwnershipCompanyInsider OwnershipATRXAdhera Therapeutics28.20%GLGLFGLG Life TechN/ANXENNexien Biopharma30.60%VIRXViracta Therapeutics10.69%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATRXAdhera Therapeutics211.63 million8.35 millionNot OptionableGLGLFGLG Life Tech1238.39 millionN/ANot OptionableNXENNexien Biopharma470.77 million49.12 millionNot OptionableVIRXViracta Therapeutics2039.74 million35.50 millionNo DataATRX, GLGLF, NXEN, and VIRX HeadlinesRecent News About These CompaniesHead-To-Head Analysis: Viracta Therapeutics (NASDAQ:VIRX) versus Zymeworks (NYSE:ZYME)August 17, 2025 | americanbankingnews.comCalif. biotech company once worth $476M lays off every remaining employeeFebruary 11, 2025 | msn.comViracta Therapeutics Terminates Employees & Winds Down OperationsFebruary 8, 2025 | contractpharma.comCViracta Therapeutics, Inc.: Viracta Therapeutics Announces Wind Down of OperationsFebruary 6, 2025 | finanznachrichten.deViracta Therapeutics Shuts Down Operations, Lays Off All StaffFebruary 6, 2025 | precisionmedicineonline.comPViracta Therapeutics terminates employees, to wind down operationsFebruary 6, 2025 | markets.businessinsider.comViracta Therapeutics to cease operations and seek alternativesFebruary 5, 2025 | msn.comViracta Therapeutics Winds Down Operations, Terminates EmployeesFebruary 5, 2025 | marketwatch.comViracta Therapeutics hits end of the line, laying off all workers and winding downFebruary 5, 2025 | fiercebiotech.comFViracta Therapeutics, Inc. Announces Employee Terminations and Wind Down of OperationsFebruary 5, 2025 | quiverquant.comQViracta Therapeutics Announces Wind Down of OperationsFebruary 5, 2025 | globenewswire.comWhy Did Viracta Therapeutics Inc (VIRX) Stock Tumble -46.67% to $0.08?February 4, 2025 | bovnews.comBVIRX stock plunges to 52-week low, touches $0.08February 3, 2025 | msn.comViracta Therapeutics to be delisted from NasdaqFebruary 3, 2025 | msn.comViracta Therapeutics strikes deal to avoid defaultJanuary 25, 2025 | msn.comViracta Therapeutics Inc (VIRX) Stock Trading RecapJanuary 10, 2025 | bovnews.comBVIRX’s Unexpected Surge: What’s Next?January 6, 2025 | bovnews.comBViracta Therapeutics Inc (VIRX) Stock Settles at $0.18: What’s Contributing to This Price Point?January 3, 2025 | bovnews.comBCash-strapped Viracta ends phase 2 study of lead cancer drug as it mulls remaining optionsJanuary 3, 2025 | fiercebiotech.comFLeerink Partners Issues Market Perform Rating for Viracta Therapeutics Inc (VIRX) StockDecember 30, 2024 | bovnews.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATRX, GLGLF, NXEN, and VIRX Company DescriptionsAdhera Therapeutics OTCMKTS:ATRX$0.01 0.00 (0.00%) As of 08/20/2025Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.GLG Life Tech OTCMKTS:GLGLFGLG Life Tech Corporation researches for, develops, grows, refines, and produces natural sweeteners extracted from the stevia plant and monk fruit in Canada and internationally. It also offers P-Pro Plus, a pea protein product; REB M GOLD, a bioconverted Rebaudioside M and Rebaudioside D. sweetener; and natural ingredients. It serves in the food and beverage industry. The company was formerly known as GLG Life Tech Limited and changed its name to GLG Life Tech Corporation in March 2007. GLG Life Tech Corporation was incorporated in 1998 and is headquartered in Richmond, Canada.Nexien Biopharma OTCMKTS:NXEN$0.0014 0.00 (-75.44%) As of 08/19/2025 03:46 PM EasternNexien BioPharma, Inc. focuses on the formulation, development, and commercialization of cannabinoid-based pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders, and medical conditions. The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018. Nexien BioPharma, Inc. is based in Glendale, Colorado.Viracta Therapeutics NASDAQ:VIRX$0.0098 0.00 (0.00%) As of 07/25/2025Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Robotics Stocks at the Heart of the Robotics Revolution Analog Devices and an AI-Driven Semiconductor Supercycle Palantir is Selling Off, BigBear.ai Could Be Your Hedge ASML Has Entered Buy Territory, But Only For Patient Investors Lowe’s Builds Value for Investors: Still a Good Buy in 2025 Target: Missing the Mark in 2025—Downtrend May Continue Toll Brothers: A Great Buy and Hold Stock With Risks in 2025 Amazon Stock Sets Up for Breakout After Bullish Crossover Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access